RESUMEN
Checkpoint blockade therapies targeting PD-1/PD-L1 and CTLA-4 are clinically successful but also evoke adverse events due to systemic T-cell activation. We engineered a bispecific, mAb targeting CD28 homolog (CD28H), a newly identified B7 family receptor that is constitutively expressed on T and natural killer (NK) cells, with a PD-L1 antibody to potentiate tumor-specific immune responses. The bispecific antibody led to T-cell costimulation, induced NK-cell cytotoxicity of PD-L1-expressing tumor cells, and activated tissue-resident memory CD8+ T cells. Mechanistically, the CD28H agonistic arm of the bispecific antibody reduced PD-L1/PD-1-induced SHP2 phosphorylation while simultaneously augmenting T-cell receptor signaling by activating the MAPK and AKT pathways. This bispecific approach could be used to target multiple immune cells, including CD8+ T cells, tissue-resident memory T cells, and NK cells, in a tumor-specific manner that may lead to induction of durable, therapeutic antitumor responses.
Asunto(s)
Anticuerpos Biespecíficos , Neoplasias , Anticuerpos Biespecíficos/metabolismo , Antígeno B7-H1/metabolismo , Antígenos CD28/metabolismo , Linfocitos T CD8-positivos , Línea Celular Tumoral , Humanos , Inmunoterapia , Células Asesinas Naturales , Activación de Linfocitos , Neoplasias/metabolismo , Receptor de Muerte Celular Programada 1/metabolismoRESUMEN
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA4 inhibition favoring enhanced blockade on PD-1+ activated T cells. We show that MEDI5752 preferentially saturates CTLA4 on PD-1+ T cells versus PD-1- T cells, reducing the dose required to elicit IL2 secretion. Unlike conventional PD-1/CTLA4 mAbs, MEDI5752 leads to the rapid internalization and degradation of PD-1. Moreover, we show that MEDI5752 preferentially localizes and accumulates in tumors providing enhanced activity when compared with a combination of mAbs targeting PD-1 and CTLA4 in vivo. Following treatment with MEDI5752, robust partial responses were observed in two patients with advanced solid tumors. MEDI5752 represents a novel immunotherapy engineered to preferentially inhibit CTLA4 on PD-1+ T cells. SIGNIFICANCE: The unique characteristics of MEDI5752 represent a novel immunotherapy engineered to direct CTLA4 inhibition to PD-1+ T cells with the potential for differentiated activity when compared with current conventional mAb combination strategies targeting PD-1 and CTLA4. This molecule therefore represents a step forward in the rational design of cancer immunotherapy.See related commentary by Burton and Tawbi, p. 1008.This article is highlighted in the In This Issue feature, p. 995.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma de Células Claras/tratamiento farmacológico , Antígeno CTLA-4/metabolismo , Humanos , Inmunoterapia , Neoplasias Renales/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Receptor de Muerte Celular Programada 1/metabolismo , Neoplasias Gástricas/tratamiento farmacológico , Linfocitos T/inmunologíaRESUMEN
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.
Asunto(s)
Antígenos CD/genética , Epítopos/inmunología , Proteínas de Punto de Control Inmunitario/genética , Tolerancia Inmunológica , Linfoma/genética , Monocitos/inmunología , Receptores Inmunológicos/genética , Animales , Anticuerpos Monoclonales/biosíntesis , Anticuerpos Monoclonales/metabolismo , Antígenos CD/inmunología , Línea Celular Tumoral , Proliferación Celular , Mapeo Epitopo , Epítopos/química , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Xenoinjertos , Humanos , Proteínas de Punto de Control Inmunitario/inmunología , Linfoma/inmunología , Linfoma/mortalidad , Linfoma/patología , Ratones , Monocitos/citología , Biblioteca de Péptidos , Cultivo Primario de Células , Receptores Inmunológicos/agonistas , Receptores Inmunológicos/inmunología , Análisis de Supervivencia , Linfocitos T/citología , Linfocitos T/inmunología , Trasplante HomólogoRESUMEN
Antigen presenting cells (APC) are critical components of innate immunity and consequently shape the adaptive response. Leukocyte Ig Like Receptors (LILR) are innate immune receptors predominantly expressed on myeloid cells. LILR can influence the antigen presenting phenotype of monocytic cells to determine the nature of T cell responses in infections including Mycobaterium leprae. We therefore investigated the relevance of LILR in the context of Mycobacterium tuberculosis. Real-time PCR studies indicated that the transcriptional profile of the orphan receptor LILRB5 was significantly up-regulated following exposure to mycobacteria. Furthermore, LILRA1 and LILRB5 were able to trigger signalling through direct engagement of mycobacteria using tranfectant cells incorporating a reporter system. We describe for the first time the expression of this receptor on T cells, and highlight the potential relevance to mycobacterial recognition. Furthermore, we demonstrate that crosslinking of this receptor on T cells increases proliferation of cytotoxic, but not helper, T cells.
Asunto(s)
Antígenos CD/metabolismo , Receptores Inmunológicos/metabolismo , Antígenos CD/genética , Vacuna BCG/inmunología , Proliferación Celular , Células Cultivadas , Células Dendríticas/metabolismo , Expresión Génica , Humanos , Inmunidad Innata , Mycobacterium tuberculosis/inmunología , Receptores Inmunológicos/genética , Linfocitos T/metabolismo , VacunaciónRESUMEN
The LILRs are a family of receptors that regulate the activities of myelomonocytic cells. We found that specific allelic variants of two related members of the LILR family, LILRB3 and LILRA6, interact with a ligand exposed on necrotic glandular epithelial cells. The extracellular domains of LILRB3 and LILRA6 are very similar and their genes are highly polymorphic. A commonly occurring allele, LILRB3*12, displayed particularly strong binding of these necrotic cells and further screening of the products of LILRB3 alleles identified motifs that correlated with binding. Immunoprecipitation of the ligand from epithelial cell lysates using recombinant LILRB3*12, identified cytokeratins 8, 18 and 19. Purified proteins obtained from epithelial cell lysates, using anti-cytokeratin 8 antibodies, were able to activate LILRB3*12 reporter cells. Knock-down of cytokeratin 8 in epithelial cells abrogated expression of the LILRB3 ligand, while staining with recombinant LILRB3*12 showed co-localisation with cytokeratin 8 and 18 in permeabilised breast cancer cells. Necrosis is a common feature of tumours. The finding of a necrosis-associated ligand for these two receptors raises the possibility of a novel interaction that alters immune responses within the tumour microenvironment. Since LILRB3 and LILRA6 genes are highly polymorphic the interaction may influence an individual's immune response to tumours.
Asunto(s)
Antígenos CD/metabolismo , Células Epiteliales/patología , Queratina-8/metabolismo , Necrosis/metabolismo , Receptores Inmunológicos/metabolismo , Alelos , Antígenos CD/genética , Antígenos CD/inmunología , Línea Celular , Células Epiteliales/metabolismo , Humanos , Necrosis/inmunología , Polimorfismo de Nucleótido Simple , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunologíaRESUMEN
We identified a novel, evolutionarily conserved receptor encoded within the human leukocyte receptor complex and syntenic region of mouse chromosome 7, named T cell-interacting, activating receptor on myeloid cells-1 (TARM1). The transmembrane region of TARM1 contained a conserved arginine residue, consistent with association with a signaling adaptor. TARM1 associated with the ITAM adaptor FcRγ but not with DAP10 or DAP12. In healthy mice, TARM1 is constitutively expressed on the cell surface of mature and immature CD11b(+)Gr-1(+) neutrophils within the bone marrow. Following i.p. LPS treatment or systemic bacterial challenge, TARM1 expression was upregulated by neutrophils and inflammatory monocytes and TARM1(+) cells were rapidly recruited to sites of inflammation. TARM1 expression was also upregulated by bone marrow-derived macrophages and dendritic cells following stimulation with TLR agonists in vitro. Ligation of TARM1 receptor in the presence of TLR ligands, such as LPS, enhanced the secretion of proinflammatory cytokines by macrophages and primary mouse neutrophils, whereas TARM1 stimulation alone had no effect. Finally, an immobilized TARM1-Fc fusion protein suppressed CD4(+) T cell activation and proliferation in vitro. These results suggest that a putative T cell ligand can interact with TARM1 receptor, resulting in bidirectional signaling and raising the T cell activation threshold while costimulating the release of proinflammatory cytokines by macrophages and neutrophils.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Citocinas/metabolismo , Macrófagos/inmunología , Neutrófilos/inmunología , Receptores Inmunológicos/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Línea Celular , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Femenino , Granulocitos/inmunología , Granulocitos/metabolismo , Células HEK293 , Antígenos HLA/genética , Humanos , Inflamación/inmunología , Ligandos , Lipopolisacáridos/inmunología , Activación de Linfocitos/genética , Activación de Linfocitos/inmunología , Macrófagos/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos NOD , Datos de Secuencia Molecular , Neutrófilos/metabolismo , Transporte de Proteínas/inmunología , Receptores Inmunológicos/genética , Proteínas Recombinantes de Fusión/inmunología , Transducción de Señal/inmunologíaRESUMEN
The human leukocyte receptor complex (LRC) encompasses several sets of genes with a common evolutionary origin and which form a branch of the immunoglobulin superfamily (IgSF). Comparisons of LRC genes both within and between species calls for a high degree of plasticity. The drive for this unprecedented level of variation is not known, but it relates in part to interaction of several LRC products with polymorphic human leukocyte antigen (HLA) class I molecules. However, the range of other proposed ligands for LRC products indicates a dynamic set of receptors that have adapted to detect target molecules relating to numerous cellular pathways. Several receptors in the complex bind a molecular signature in collagenous ligands. Others detect a variety of motifs relating to pathogens in addition to cellular stress, attesting to the opportunistic versatility of LRC receptors.
Asunto(s)
Antígenos HLA/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Células Asesinas Naturales/inmunología , Leucocitos/inmunología , Receptores Inmunológicos/inmunología , Variación Genética/genética , Variación Genética/inmunología , Antígenos HLA/genética , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Células Asesinas Naturales/metabolismo , Leucocitos/metabolismo , Ligandos , Modelos Genéticos , Modelos Inmunológicos , Receptores Inmunológicos/genéticaRESUMEN
Natural progression of HIV-1 infection depends on genetic variation in the human major histocompatibility complex (MHC) class I locus, and the CD8+ T cell response is thought to be a primary mechanism of this effect. However, polymorphism within the MHC may also alter innate immune activity against human immunodeficiency virus type 1 (HIV-1) by changing interactions of human leukocyte antigen (HLA) class I molecules with leukocyte immunoglobulin-like receptors (LILR), a group of immunoregulatory receptors mainly expressed on myelomonocytic cells including dendritic cells (DCs). We used previously characterized HLA allotype-specific binding capacities of LILRB1 and LILRB2 as well as data from a large cohort of HIV-1-infected individuals (N = 5126) to test whether LILR-HLA class I interactions influence viral load in HIV-1 infection. Our analyses in persons of European descent, the largest ethnic group examined, show that the effect of HLA-B alleles on HIV-1 control correlates with the binding strength between corresponding HLA-B allotypes and LILRB2 (p = 10(-2)). Moreover, overall binding strength of LILRB2 to classical HLA class I allotypes, defined by the HLA-A/B/C genotypes in each patient, positively associates with viral replication in the absence of therapy in patients of both European (p = 10(-11)-10(-9)) and African (p = 10(-5)-10(-3)) descent. This effect appears to be driven by variations in LILRB2 binding affinities to HLA-B and is independent of individual class I allelic effects that are not related to the LILRB2 function. Correspondingly, in vitro experiments suggest that strong LILRB2-HLA binding negatively affects antigen-presenting properties of DCs. Thus, we propose an impact of LILRB2 on HIV-1 disease outcomes through altered regulation of DCs by LILRB2-HLA engagement.
Asunto(s)
Infecciones por VIH/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Inmunidad Innata/genética , Glicoproteínas de Membrana/genética , Receptores Inmunológicos/genética , Alelos , Linfocitos T CD8-positivos/inmunología , Células Dendríticas/inmunología , Femenino , Infecciones por VIH/genética , Infecciones por VIH/virología , VIH-1/genética , VIH-1/inmunología , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Glicoproteínas de Membrana/inmunología , Receptores Inmunológicos/inmunología , Carga Viral/genética , Carga Viral/inmunologíaRESUMEN
Leukocyte immunoglobulin-like receptors (LILR) are cell surface molecules that regulate the activities of myelomonocytic cells through the balance of inhibitory and activation signals. LILR genes are located within the leukocyte receptor complex (LRC) on chromosome 19q13.4 adjacent to KIR genes, which are subject to allelic and copy number variation (CNV). LILRB3 (ILT5) and LILRA6 (ILT8) are highly polymorphic receptors with similar extracellular domains. LILRB3 contains inhibitory ITIM motifs and LILRA6 is coupled to an adaptor with activating ITAM motifs. We analysed the sequences of the extracellular immunoglobulin domain-encoding regions of LILRB3 and LILRA6 in 20 individuals, and determined the copy number of these receptors, in addition to those of other members of the LILR family. We found 41 polymorphic sites within the extracellular domains of LILRB3 and LILRA6. Twenty-four of these sites were common to both receptors. LILRA6, but not LILRB3, exhibited CNV. In 20 out of 48 human cell lines from the International Histocompatibility Working Group, LILRA6 was deleted or duplicated. The only other LILR gene exhibiting genomic aberration was LILRA3, in this case due to a partial deletion.
Asunto(s)
Antígenos CD/genética , Cromosomas Humanos Par 19 , Variaciones en el Número de Copia de ADN , Monocitos/metabolismo , Polimorfismo Genético , Receptores Inmunológicos/genética , Alelos , Secuencias de Aminoácidos , Antígenos CD/inmunología , Secuencia de Bases , Línea Celular , Duplicación de Gen , Expresión Génica , Humanos , Datos de Secuencia Molecular , Monocitos/citología , Monocitos/inmunología , Estructura Terciaria de Proteína , Receptores Inmunológicos/inmunología , Análisis de Secuencia de ADN , Eliminación de Secuencia , Transducción de SeñalRESUMEN
Leukocyte Immunoglobulin-like receptors (LILR) are innate immune receptors involved in regulating both innate and adaptive immune functions. LILR show more interspecies conservation than the closely related Killer Ig-like receptors, and homologues have been identified in rodents, primates, seals and chickens. The murine equivalents, paired Ig-like receptors (PIR), contain two additional immunoglobulin domains, but show strong sequence and functional similarities to human LILR. The bovine genome was recently sequenced, with preliminary annotations indicating that LILR were present in this species. We therefore sought to identify and characterize novel LILR within the Bos taurus genome, compare these phylogenetically with LILR from other species and determine whether they were expressed in vivo. Twenty six potential bovine LILR were initially identified using BLAST and BLAT software. Phylogenetic analysis constructed using the neighbour-joining method, incorporating pairwise deletion and confidence limits estimated from 1000 replicates using bootstrapping, indicated that 16 of these represent novel bovine LILR. Protein structures defined using protein BLAST predict that the bovine LILR family comprises seven putative inhibitory, four activating and five soluble receptors. Preliminary expression analysis was performed by mapping the predicted sequences with raw data from total transcript sequence generated using Genome Analyzer IIx (Illumina) to provide evidence that all 16 of these receptors are expressed in vivo. The bovine receptor family appears to contain receptors which resemble the six domain rodent PIR as well as the four domain LILR found in other species.
Asunto(s)
Receptores Inmunológicos/genética , Animales , Bovinos , Células Cultivadas , Mapeo Cromosómico , Expresión Génica , Humanos , Leucocitos Mononucleares/metabolismo , Ratones , Modelos Moleculares , Filogenia , Estructura Terciaria de Proteína , Receptores Inmunológicos/química , Receptores Inmunológicos/metabolismo , Análisis de Secuencia de Proteína , Homología de Secuencia de AminoácidoRESUMEN
Leukocyte Ig-like receptors (LILRs) are a family of innate immune receptors predominantly expressed by myeloid cells that can alter the Ag presentation properties of macrophages and dendritic cells. Several LILRs bind HLA class I. Altered LILR recognition due to HLA allelic variation could be a contributing factor in disease. We comprehensively assessed LILR binding to >90 HLA class I alleles. The inhibitory receptors LILRB1 and LILRB2 varied in their level of binding to different HLA alleles, correlating in some cases with specific amino acid motifs. LILRB2 displayed the weakest binding to HLA-B*2705, an allele genetically associated with several autoimmune conditions and delayed progression of HIV infection. We also assessed the effect of HLA class I conformation on LILR binding. LILRB1 exclusively bound folded ß(2)-microglobulin-associated class I, whereas LILRB2 bound both folded and free H chain forms. In contrast, the activating receptor LILRA1 and the soluble LILRA3 protein displayed a preference for binding to HLA-C free H chain. To our knowledge, this is the first study to identify the ligand of LILRA3. These findings support the hypothesis that LILR-mediated detection of unfolded versus folded MHC modulates immune responses during infection or inflammation.
Asunto(s)
Alelos , Genes MHC Clase I/inmunología , Antígenos HLA/genética , Glicoproteínas de Membrana/metabolismo , Receptores Inmunológicos/metabolismo , Secuencias de Aminoácidos/inmunología , Secuencia de Aminoácidos , Células HEK293 , Antígeno HLA-B27/genética , Antígeno HLA-B27/metabolismo , Antígenos HLA-C/genética , Antígenos HLA-C/metabolismo , Humanos , Glicoproteínas de Membrana/genética , Células Mieloides/inmunología , Células Mieloides/metabolismo , Unión Proteica/genética , Unión Proteica/inmunología , Conformación Proteica , Pliegue de Proteína , Receptores Inmunológicos/genética , Microglobulina beta-2/deficiencia , Microglobulina beta-2/genética , Microglobulina beta-2/metabolismoRESUMEN
Testis-specific gene antigen 10 (TSGA10) encodes an 82-kDa protein expressed during development, and in testis and brain tissues. We report its expression in human monocyte-derived dendritic cells (DC) and macrophages in vitro and in murine spleen CD11c(+) cells ex vivo. An interaction between DC/macrophage-derived TSGA10 and vimentin, as well as a few other major cytoskeletal proteins (e.g., actin-γ1), was identified by pull-down and mass spectroscopy assays. The interaction between TSGA10 and vimentin was further confirmed by immunoprecipitation and immunolocalisation in transfected RAW267 and HEK293 cell lines. TSGA10 formed filamentous structures in transfected COS-1 cells and was observed in cellular projections. We propose that TSGA10 could influence the function of antigen presenting cells (APC) via its interaction with cytoskeletal proteins such as vimentin.
Asunto(s)
Células Dendríticas/metabolismo , Proteínas/metabolismo , Vimentina/metabolismo , Actinas/metabolismo , Animales , Antígeno CD11c , Línea Celular , Proteínas del Citoesqueleto , Citoesqueleto/inmunología , Citoesqueleto/metabolismo , Células Dendríticas/inmunología , Humanos , Macrófagos/inmunología , Macrófagos/metabolismo , Masculino , Espectrometría de Masas , Ratones , Monocitos/citología , Monocitos/inmunología , Monocitos/metabolismo , Unión Proteica , Bazo/citología , Bazo/inmunología , Testículo/inmunología , Testículo/metabolismoRESUMEN
BACKGROUND: Leukocyte Ig-like receptors (LILR) are a family of innate immune receptors with immunomodulatory functions. High-level expression of the receptors LILRB2 (ILT4) and LILRB4 (ILT3) is a feature of tolerogenic antigen presenting cells and has been observed in cancer and transplant situations. There are relatively few studies regarding these receptors in the context of infection and it is not yet clear how LILRB4 exerts its inhibitory effects. RESULTS: We studied the effects of LILRB4 ligation on antigen presenting cell phenotype, and the expression of LILRB2 and LILRB4 on Salmonella-infected antigen presenting cells. Ligation of LILRB4 throughout in vitro culture of dendritic cells led to an upregulation of the co-stimulatory protein CD86. Alterations in the production of IL-8 and IL-10 by LILRB4-ligated macrophages were also observed. Infection with Salmonella typhimurium or TLR stimulation with Salmonella components led to an upregulation of LILRB2 and LILRB4. CONCLUSION: Our results indicate that the inhibitory effects of LILRB4 do not result from a failure to upregulate co-stimulatory proteins. In addition to the high level expression that can render antigen presenting cells tolerogenic, there may be a role for lower level expression and activity of LILRB2 and LILRB4 in response to TLR signalling during an immune response to bacterial infection.
Asunto(s)
Glicoproteínas de Membrana/biosíntesis , Receptores de Superficie Celular/metabolismo , Receptores Inmunológicos/biosíntesis , Infecciones por Salmonella/inmunología , Salmonella typhimurium/inmunología , Células Presentadoras de Antígenos/inmunología , Células Presentadoras de Antígenos/metabolismo , Células Presentadoras de Antígenos/patología , Antígeno B7-2/biosíntesis , Antígeno B7-2/genética , Antígeno B7-2/inmunología , Células Cultivadas , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Células Dendríticas/microbiología , Células Dendríticas/patología , Regulación hacia Abajo , Humanos , Inmunofenotipificación , Interleucina-10/metabolismo , Interleucina-8/metabolismo , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/patología , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/inmunología , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/inmunología , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunología , Infecciones por Salmonella/genética , Infecciones por Salmonella/metabolismo , Infecciones por Salmonella/patología , Salmonella typhimurium/patogenicidad , Regulación hacia ArribaRESUMEN
Salmonella typhimurium is a facultative pathogen capable of entering and replicating in both professional and non-professional antigen presenting cells. Control of infection requires MHC class II restricted CD4 T-helper cell responses. Here we show that Salmonella infection induced polyubiquitination of HLA-DR, a post-translational modification that led to removal of mature, peptide loaded, alphabeta dimers from the cell surface. Immature alphabetaIi complexes were unaffected. Surface expression of all class II isotypes, HLA-DP, -DQ, and -DR, was reduced in infected cells, but other cell-surface molecules that traffic through class II peptide loading compartments were unaffected. A Salmonella strain carrying a mutation in ssaV did not induce ubiquitination of class II, implicating Salmonella T3SS-2 effector proteins in the process. T3SS-2 effectors, with established or proposed roles in ubiquitination, were not required for class II down-regulation, suggesting that an additional T3SS-2 effector is involved in regulating MHC class II ubiquitination. Although recognized as a viral immune evasion strategy, here, we demonstrate that bacteria can control surface MHC expression through ubiquitination.
Asunto(s)
Regulación Bacteriana de la Expresión Génica , Antígenos de Histocompatibilidad Clase II/metabolismo , Salmonella/metabolismo , Ubiquitina/metabolismo , Secuencia de Aminoácidos , Linfocitos T CD8-positivos/metabolismo , Membrana Celular/metabolismo , Separación Celular , Citoplasma/metabolismo , Citometría de Flujo , Células HeLa , Antígenos de Histocompatibilidad Clase II/química , Humanos , Modelos Biológicos , Datos de Secuencia Molecular , Infecciones por Salmonella/metabolismoRESUMEN
Leucocyte Ig-like receptors (LILR) are a family of innate immune receptors expressed on myeloid and lymphoid cells that influence adaptive immune responses. We identified a common mechanism of alternative mRNA splicing, which generates transcripts that encode soluble protein isoforms of the majority of human LILR. These alternative splice variants lack transmembrane and cytoplasmic encoding regions, due to the transcription of a cryptic stop codon present in an intron 5' of the transmembrane encoding exon. The alternative LILR transcripts were detected in cell types that express their membrane-associated isoforms. Expression of the alternative LILRB1 transcript in transfected cells resulted in the release of a soluble approximately 65 Kd LILRB1 protein into culture supernatants. Soluble LILRB1 protein was also detected in the culture supernatants of monocyte-derived DC. In vitro assays suggested that soluble LILRB1 could block the interaction between membrane-associated LILRB1 and HLA-class I. Soluble LILRB1 may act as a dominant negative regulator of HLA-class I-mediated LILRB1 inhibition. Soluble isoforms of the other LILR may function in a comparable way.
Asunto(s)
Empalme Alternativo/genética , Empalme Alternativo/inmunología , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunología , Antígenos CD/genética , Western Blotting , Diferenciación Celular/genética , Diferenciación Celular/inmunología , Separación Celular , Codón , Células Dendríticas/citología , Células Dendríticas/inmunología , Citometría de Flujo , Expresión Génica , Humanos , Focalización Isoeléctrica , Receptor Leucocitario Tipo Inmunoglobulina B1 , Macrófagos/inmunología , Glicoproteínas de Membrana/genética , Monocitos/inmunología , Isoformas de Proteínas/genética , Isoformas de Proteínas/inmunología , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transcripción GenéticaRESUMEN
KIR3DL3 is a framework gene of the Leukocyte Receptor Complex, present in all individuals and haplotypes analysed to date. We describe 17 novel KIR3DL3 alleles, including seven single nucleotide polymorphic (SNP) positions within the coding region. Sequence variation within introns included a VNTR within intron 1. As KIR3DL3 mRNA is known to be expressed in decidual NK cells, we investigated the impact of KIR3DL3 allelic variation on pre-eclampsia. No statistical difference in allele frequency or polymorphism was observed between pre-eclampsia patient and control cohorts. Linkage disequilibrium (LD) analysis of exonic SNPs suggested that recombination may be a mechanism of generating sequence diversity within KIR3DL3. A potential recombination hotspot was located within intron 5. A strong LD was detected between polymorphism in exon 6 of KIR3DL3 and the KIR gene -2DL3 or -2DS2 loci, which define the centromeric end of two main haplotypes (A and B) of the KIR cluster. Comparison of primate KIR sequences indicated that the Ig domains of KIR3DL3 are highly conserved between chimpanzee, gorilla and humans. Investigation of KIR3DL3 dN/dS ratios indicated a greater level of synonymous mutations consistent with purifying selection, although positive selection was detected acting on two sites within the stem region.
Asunto(s)
Alelos , Variación Genética , Polimorfismo de Nucleótido Simple/genética , Preeclampsia/genética , Receptores Inmunológicos/genética , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Frecuencia de los Genes , Humanos , Intrones , Células Asesinas Naturales/inmunología , Desequilibrio de Ligamiento , Filogenia , Preeclampsia/inmunología , Embarazo , Receptores Inmunológicos/inmunología , Receptores KIR , Receptores KIR2DL3 , Recombinación Genética , Selección GenéticaRESUMEN
Azathioprine metabolism is influenced by activity of the enzyme thiopurine S-methyltransferase (TPMT), which varies markedly between individuals. In this study we examined the influence of TPMT gene polymorphisms on azathioprine dose 1 year after renal transplantation. TPMT coding and promoter genotypes were determined using PCR-based assays. Azathioprine dose, white cell count, and intercurrent events throughout the first year after renal transplantation were ascertained from contemporaneous clinical notes. All patients analysed ( n=172) received an initial azathioprine dose of 1.5 mg/kg per day. Twelve individuals with one variant TPMT coding allele were detected (*3A n=11, *3C n=1). Of these, 58% required azathioprine dose reduction because of leucopenia, compared to only 30% of homozygous wild-type patients ( P=0.04). A significant correlation between the presence of >/=11 variable number tandem repeats (VNTRs) in the TPMT promoter and reduction in azathioprine dose was also identified ( P=0.001). We concluded that when azathioprine is administered at an initial dose of 1.5 mg/kg per day, both coding and promoter TPMT polymorphisms influence the dose tolerated.
Asunto(s)
Azatioprina/administración & dosificación , Inmunosupresores/administración & dosificación , Trasplante de Riñón , Metiltransferasas/genética , Polimorfismo Genético , Azatioprina/efectos adversos , Azatioprina/uso terapéutico , Relación Dosis-Respuesta a Droga , Frecuencia de los Genes , Genotipo , Humanos , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Leucopenia/inducido químicamente , Regiones Promotoras Genéticas , Estudios Retrospectivos , Secuencias Repetidas en Tándem , Factores de TiempoRESUMEN
BACKGROUND: Intracellular concentration of reactive oxygen species is held within tight physiological limits by enzymes with scavenging and repair functions. Under extreme conditions such as prolonged cold ischemia, these enzymes may be unable to adequately protect the organ, resulting in reperfusion injury that renders the graft dysfunctional after transplantation. In this study, we investigated normal human variation of some of these inducible enzymes to determine if certain phenotypes could be identified that are associated with a reduced risk of delayed graft function (DGF). METHODS: Polymerase chain reaction was performed to differentiate polymorphisms for manganese superoxide dismutase and three classes of glutathione-S-transferase in donors and recipients of transplants with over 24 hr of cold ischemia. The data attained was analyzed compared with the presence or absence of DGF, defined as the requirement of hemodialysis in the first week after transplantation. RESULTS: Enzyme polymorphisms were defined for 229 recipients and 104 of their respective donors. Patients receiving a kidney from a donor who expressed GSTM1*B either alone or in combination with GSTM1*A experienced significantly lower rates of DGF (P <0.05). No association was found between any enzyme polymorphism in the recipients and the development of DGF. CONCLUSIONS: The identification of a genetic allele, which is protective against reperfusion injury, generates the possibility for defining polymorphisms at the time of tissue typing to give insight to the inherent biological risk of DGF that an organ possesses.